At this point, though, I can say that this should be a very positive step towards establishing beyond any doubt another therapeutic option for patients with GIST using a novel molecularly-targeted agent if Gleevec proves inadequate to control the disease.
This is a good (if expected) step, but the company is going to have to go far beyondthis to regain the share it continues to lose in the mobile device market.